CDx Diagnostics showcases WATS3D test findings at DDW 2025

In the United States, on May 2, 2025, CDx Diagnostics announced the selection of new clinical data for podium presentation at the 2025 Digestive Disease Week (DDW) in San Diego. This conference is a key event for professionals in gastroenterology and allows for the sharing of significant advancements in the field. The data supporting the WATS3D test, which is aimed at screening and monitoring Barrett's esophagus and dysplasia, will be presented by Dr. Nicholas J. Shaheen along with co-researchers. This test has shown promising results in enhancing early detection rates compared to conventional techniques. The WATS3D test operates differently than traditional forceps biopsy methods. It collects a larger sample of mucosal tissue and employs advanced 3D imaging technology to analyze cellular material, thereby increasing the likelihood of identifying Barrett's esophagus and related complications that could otherwise remain undiagnosed. According to the available data, conventional forceps biopsy may miss as much as 50% of cases, a significant statistic underscoring the importance of innovative diagnostic techniques like WATS3D. The presentations at DDW 2025 will highlight important progress in understanding the condition's biological significance and cancer progression risks. During the event, key insights will be shared, including information gathered from a large cohort of more than 3,500 patients that suggests that the presence of MUC2 in tissue samples may indicate neoplastic progression as reliably as the presence of goblet cells, a traditional marker in Barrett's esophagus assessments. These findings could potentially alter the understanding and clinical practices regarding esophageal disease monitoring, leading to improved patient outcomes through early intervention strategies. The broader implications of this research are evident as CDx Diagnostics aims to empower healthcare providers to identify patients who require prompt intervention. The new findings presented at DDW will likely contribute to a shift in how Barrett's esophagus and its potential progression to esophageal cancer are diagnosed and treated, ultimately aiming to reduce the time to treatment and enhance overall patient care.